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Introduction {#jdi12167-sec-0005}
============

Diabetes mellitus (DM) is a common chronic disease worldwide, and the global health expenditure on DM is expected be at least 376 billion US dollars in 2010 and 490 billion US dollars in 2030[1](#jdi12167-bib-0001){ref-type="ref"}. Especially among Asian countries, the prevalence of DM has rapidly increased in recent decades with economic development accompanied by changes in food supply and dietary patterns, technology transfer, and cultural admixtures[2](#jdi12167-bib-0002){ref-type="ref"}.

In diabetic patients, the proportion of ischemic heart disease (IHD) is two‐ to fourfold higher[3](#jdi12167-bib-0003){ref-type="ref"}, the risk of stroke is approximately twofold greater[4](#jdi12167-bib-0004){ref-type="ref"} and the risk of peripheral arterial disease (PAD) is approximately fourfold greater[5](#jdi12167-bib-0005){ref-type="ref"} than in non‐diabetic patients. In Japan, DM was reported as a risk factor for cardiovascular disease and coronary heart disease[6](#jdi12167-bib-0006){ref-type="ref"}, and DM is related to coronary heart disease among women and ischemic stroke among both sexes[7](#jdi12167-bib-0007){ref-type="ref"}. In addition, large nationwide cohort studies in Japan have suggested that DM and elevated glucose levels are associated with incident coronary heart disease[8](#jdi12167-bib-0008){ref-type="ref"} and ischemic stroke[9](#jdi12167-bib-0009){ref-type="ref"} in the general Japanese population.

In Japan, the National Diabetic Patients Survey reported that approximately 8.9 million people were strongly suspected of having DM[10](#jdi12167-bib-0010){ref-type="ref"}. Nevertheless, according to the National Health and Nutrition Survey carried out in 2009, just 2.37 million people received treatment for DM[11](#jdi12167-bib-0011){ref-type="ref"}.

The Japanese government developed a set of indicators for health promotion for the period of 2001--2010, which is called "Healthy Japan 21" in financial year 2000. The midcourse review of these indicators reported that the proportion of adherence to treatment for DM and health guidance after health examinations slightly increased, but did not reach the targets[12](#jdi12167-bib-0012){ref-type="ref"}. Subsequently, the number of patients with diabetic complications had increased beyond the target[13](#jdi12167-bib-0013){ref-type="ref"}.

However, there is no evidence of the effect of regular visits to physicians on in‐hospital mortality of diabetic patients or the number of diabetic complications in Japan. Therefore, the objective of the present study was to evaluate the effect of irregular visits on diabetic macrovascular complications and in‐hospital mortality among diabetic patients.

Materials and Methods {#jdi12167-sec-0006}
=====================

Data Source {#jdi12167-sec-0007}
-----------

We obtained data of diabetic patients who were newly hospitalized to the general ward between April 2010 and September 2010 from fee‐for‐service claims data of the Fukuoka National Health Insurance Organization. We combined them with medical claims data of outpatient visits between April 2009 and March 2010. We assessed only the first hospitalizations among patients who had experienced several hospitalizations, after excluding patients who had received hemodialysis or peritoneal dialysis. From a previous study using Japanese medical claims data of fee‐for‐service[14](#jdi12167-bib-0014){ref-type="ref"}, we identified diabetic patients by the diagnostic code of DM (International Classification of Diseases 10th revision \[ICD‐10\] codes: E10--14) that they received when they were hospitalized.

Definition of Variables {#jdi12167-sec-0008}
-----------------------

Study variables included hospitalization for diabetic macrovascular complications, outcomes at discharge, age, sex, comorbidities and the use of insulin or oral hypoglycemic agents. Because Japanese medical claims data of the fee‐for‐service system often contain information on multiple diseases, diagnostic examinations and therapies, we converted primary diagnostic codes into six‐digit codes of the Diagnosis Procedure Combination/Per‐Diem Payment System (DPC/PDPS), which is a Japanese prospective payment system[15](#jdi12167-bib-0015){ref-type="ref"}. Then, we combined the six‐digit diagnostic codes (base DPC), those of surgical procedures, adjuvant therapies and other diagnostic codes as comorbidities/complications, into 14‐digit DPC codes. Finally, we estimated the most resource‐intensive diseases by hospitalization costs, which were calculated based on the reimbursement rule of the DPC/PDPS, and defined these diseases as the primary disease. We also defined hospitalization for diabetic macrovascular complications, including IHD, stroke and PAD, as shown in Table [1](#jdi12167-tbl-0001){ref-type="table-wrap"}.

###### Definition of diabetic macrovascular complications and International Classification of Diseases, 10th Revision codes for them

  Diabetic macrovascular complications   Base DPC codes                                                                    Base DPC name                                                  ICD‐10 codes
  -------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  All strokes                                                                                                                                                                             
  Hemorrhagic stroke                     010020                                                                            Subarachnoid hemorrhage, Unruptured cerebral aneurysm          I60.x
  010040                                 Non‐traumatic intracranial hematoma(except for non‐traumatic subdural hematoma)   I61.x, I62.9, I68.0, Q28.0--Q28.3                              
  010050                                 Non‐traumatic subdural hematoma                                                   I62.0, I62.1                                                   
  Ischemic stroke                        010060                                                                            Ischemic stroke                                                G45.x, G46.x, I63.x, I65.x, I66.x, I67.5, I67.9, I69.3, I97.8
  All ischemic heart diseases                                                                                                                                                             
  AMI                                    050030                                                                            Acute myocardial infarction, recurrent myocardial infarction   I21.x, I22.x, I24.x
  IHDs exept AMI                         050050                                                                            Angina pectoris, chronic myocardial infarction                 I20.x, I25.x
  PAD                                    050170                                                                            Arteriosclerosis obliterans                                    I74.0, I74.1, I74.2, I74.3, I74.4, I74.5, I74.8, I74.9, I70.0, I70.2, I70.8, I70.9, I72.0, I72.1, I72.4, I73.x

AMI, acute myocardial infarction; DPC, Diagnosis Procedure Combination; ICD‐10, International Classification of Diseases, 10th Revision; IHDs, ischemic heart diseases; PAD, peripheral arterial disease.
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Regular visits were defined as physician visits for DM at least every 3 months between April 2009 and March 2010, whereas other visits or no visits were defined as irregular visits. In other words, we counted months of physician visits by every quarter of the year, and defined physician visits throughout every quarter as regular visits. This timing was chosen because the expiry time of prescriptions is 3 months in the Japanese system of health insurance. Age was categorized into three groups: 64 years or younger, 65--74 years and 75 years or older. Medication for DM during hospitalization was categorized into four groups: no medication, oral hypoglycemic agents, insulin, and oral hypoglycemic agents and insulin. Other lifestyle‐related diseases (hypertension \[I10\] and hyperlipidemia \[E78.0--78.5\]) were assessed using ICD‐10 codes from medical claims data during hospitalization. Furthermore, other comorbidities during hospitalization were assessed using ICD‐10 codes and the Charlson Comorbidity Index (CCI) for all conditions, except for mild diabetes, diabetes with complications, cerebral vascular disease, acute myocardial infarction and unspecified peripheral vascular disease (I73.9)[16](#jdi12167-bib-0016 jdi12167-bib-0017){ref-type="ref"}. The CCI was categorized into three categories: 0, 1 or 2, and 3 or higher[18](#jdi12167-bib-0018){ref-type="ref"}.

Statistical Analysis {#jdi12167-sec-0009}
--------------------

Patient characteristics were constructed using frequencies and proportions for categorical variables, and using median and interquartile range for a continuous variable. Categorical variables were compared between the regular visit and irregular visit groups by Pearson\'s χ^2^‐tests, and the continuous variable was compared between the two groups by the Mann--Whitney test.

Propensity score matching was carried out to formulate a balanced 1:1 matched study, and to compare risks of hospitalization for diabetic macrovascular complications and in‐hospital mortality between the regular visit and irregular visit groups. According to previous studies on variable selection of propensity score matching[19](#jdi12167-bib-0019 jdi12167-bib-0020){ref-type="ref"}, propensity scores were calculated by a logistic regression model to identify the relationships between irregular visits and sex, age, hypertension, hyperlipidemia, other comorbidities indicated in the CCI, and dummy variables for 62 residential municipalities in Fukuoka Prefecture (i.e., 61 variables). The Hosmer--Lemeshow test and the C statistic were used as an indicator of how well the logistic regression model fitted the data. Using the [spss]{.smallcaps} macro for propensity score matching[21](#jdi12167-bib-0021){ref-type="ref"}, each patient of the irregular visit group was matched with a unique control of the regular visit group within a caliper width of 0.02[22](#jdi12167-bib-0022){ref-type="ref"}. Finally, we assigned 5,940 patients to each group, and the C statistic was 0.620. The Hosmer--Lemeshow test did not reject the null hypothesis (*P* = 0.227).

Multiple logistic regression analyses were used to estimate adjusted odds ratios (AORs) and 95% confidence intervals (95% CIs) for irregular visits. For the first model, we set hospitalization for diabetic macrovascular complications as the dependent variable, and age, sex, hypertension, hyperlipidemia, medication for DM, and irregular visits as independent variables. For the second model, we set in‐hospital mortality as the dependent variable, and independent variables included those in the first model, as well as the CCI. Statistical analyses were carried out using [pasw]{.smallcaps} version 18.0 (SPSS Inc., Chicago, IL, USA), and *P*‐values \<0.05 were regarded as statistically significant.

Results {#jdi12167-sec-0010}
=======

Descriptive Statistics {#jdi12167-sec-0011}
----------------------

We identified 4,015 patients in the irregular visit group and 4,121 patients in the regular visit group. Patient characteristics are shown in Table [2](#jdi12167-tbl-0002){ref-type="table-wrap"}. The proportion of those aged 75 years or older in the regular visit group was significantly higher than that in the irregular visit group. The median number of months of physician visits in the regular visit group was 11 months (interquartile range \[IQR\] 3), whereas that in the regular visit group was 2 months (IQR 5). The proportion of patients who received medications for DM in the regular visit group was significantly higher than that in the irregular visit group. The proportion of patients who had congestive heart failure in the regular visit group was significantly less than that in the irregular visit group, and the proportion of those who had pulmonary disease, cancer, or rheumatological disease was significantly higher than that in the irregular visit group. The proportion of patients who had hypertension or hyperlipidemia in the regular visit group was significantly higher than that in the irregular visit group. The proportion of patients hospitalized for AMI, IHDs except AMI, all IHDs, hemorrhagic stroke or all strokes in the regular visit group was significantly less than that in the irregular visit group. The mortality rate in the regular visit group was significantly less than that in the irregular visit group.

###### Patient characteristics according to physician visits

                                                                  Total (*n* = 8,136)   Regular visit group (*n* = 4,121)   Irregular visit group (*n* = 4,015)   *P*‐value 
  --------------------------------------------------------------- --------------------- ----------------------------------- ------------------------------------- ------------------------------------------------
  Median age (years) \[interquartile range\]                      77 \[13\]             78 \[12\]                           77 \[12\]                             0.133[a](#jdi12167-note-0002){ref-type="fn"}
  Age (years)                                                                                                                                                     
  \<65                                                            955 (11.7%)           437 (10.6%)                         518 (12.9%)                           0.001
  65--74                                                          2,107 (25.9%)         1,114 (27.0%)                       993 (24.7%)                           
  75≦                                                             5,074 (62.4%)         2,570 (62.4%)                       2,504 (62.4%)                         
  Sex                                                                                                                                                             
  Male                                                            4,191 (51.5%)         2,150 (52.2%)                       2,041 (50.8%)                         0.228
  Female                                                          3,945 (48.5%)         1,971 (47.8%)                       1,974 (49.2%)                         
  Median no. months of physician visits \[interquartile range\]   7 \[9\]               11 \[3\]                            2 \[5\]                               \<0.001[a](#jdi12167-note-0002){ref-type="fn"}
  Medication for diabetes                                                                                                                                         
  No medication                                                   4,382 (53.9%)         1,975 (47.9%)                       2,407 (60.0%)                         \<0.001
  OHA                                                             1,925 (23.7%)         1,150 (27.9%)                       775 (19.3%)                           
  Insulin                                                         1,023 (12.6%)         523 (12.7%)                         500 (12.5%)                           
  OHA + Insulin                                                   806 (9.9%)            473 (11.5%)                         333 (8.3%)                            
  Comorbidity                                                                                                                                                     
  AIDS/HIV                                                        0 (0.0%)              0 (0.0%)                            0 (0.0%)                              --
  Congestive heart failure                                        2,379 (29.2%)         1,164 (28.2%)                       1,215 (30.3%)                         0.046
  Chronic pulmonary disease                                       1,620 (19.9%)         870 (21.1%)                         750 (18.7%)                           0.006
  Dementia                                                        415 (5.1%)            208 (5.0%)                          207 (5.2%)                            0.824
  Hemiplegia or paraplegia                                        192 (2.4%)            98 (2.4%)                           94 (2.3%)                             0.913
  Mild liver disease                                              645 (7.9%)            349 (8.5%)                          296 (7.4%)                            0.067
  Moderate or severe liver disease                                202 (2.5%)            108 (2.6%)                          94 (2.3%)                             0.418
  Cancer                                                          1,620 (19.9%)         860 (20.9%)                         760 (18.9%)                           0.028
  Metastatic solid tumor                                          353 (4.3%)            188 (4.6%)                          165 (4.1%)                            0.317
  Peripheral vascular disease                                     274 (3.4%)            132 (3.2%)                          142 (3.5%)                            0.404
  Peptic ulcer disease                                            1,816 (22.3%)         911 (22.1%)                         905 (22.5%)                           0.638
  Rheumatological disease                                         332 (4.1%)            192 (4.7%)                          140 (3.5%)                            0.008
  Renal disease                                                   791 (9.7%)            420 (10.2%)                         371 (9.2%)                            0.148
  Charlson Comorbidity Index                                                                                                                                      
  0                                                               2,491 (30.6%)         1,221 (29.6%)                       1,270 (31.6%)                         0.107
  1--2                                                            3,423 (42.1%)         1,744 (42.3%)                       1,679 (41.8%)                         
  3≦                                                              2,222 (27.3%)         1,156 (28.1%)                       1,066 (26.6%)                         
  Other lifestyle‐related disease                                                                                                                                 
  Hypertension                                                    5,327 (65.5%)         2,825 (68.6%)                       2,502 (62.3%)                         \<0.001
  Hyperglycemia                                                   2,985 (36.7%)         1,654 (40.1%)                       1,331 (33.2%)                         \<0.001
  Hospitalizations for diabetic macrovascular complications                                                                                                       
  AMI                                                             62 (0.8%)             17 (0.4%)                           45 (1.1%)                             \<0.001
  IHDs except AMI                                                 572 (7.0%)            266 (6.5%)                          306 (7.6%)                            0.040
  All IHDs                                                        634 (7.8%)            283 (6.9%)                          351 (8.7%)                            0.002
  Hemorrhagic stroke                                              69 (0.8%)             24 (0.6%)                           45 (1.1%)                             0.008
  Ischemic stroke                                                 416 (5.1%)            196 (4.8%)                          220 (5.5%)                            0.139
  All strokes                                                     485 (6.0%)            220 (5.3%)                          265 (6.6%)                            0.016
  PAD                                                             95 (1.2%)             51 (1.2%)                           44 (1.1%)                             0.552
  Diabetic macrovascular complications                            1,214 (14.9%)         554 (13.4%)                         660 (16.4%)                           \<0.001
  In‐hospital mortality                                           615 (7.6%)            268 (6.5%)                          347 (8.6%)                            \<0.001 

Compared by Mann‐Whitney test. Other comparisons made using χ^2^‐test. AIDS/HIV, acquired immunodeficiency syndrome/human immunodeficiendy virus; AMI, acute myocardial infarction; IHDs, ischemic heart diseases; OHA, oral hypoglycemic agents; PAD, peripheral arterial disease.
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After propensity score matching, the proportion of patients who had congestive heart failure in the regular visit group was significantly less than that in the irregular visit group, and the proportion of those who had pulmonary disease or cancer was significantly higher than that in the irregular visit group (Table [3](#jdi12167-tbl-0003){ref-type="table-wrap"}).

###### Patient characteristics according to physician visits after propensity score matching

                                                                  Total (*n *= 5,940)   Regular visit group (*n* = 2,970)   Irregular visit group (*n* = 2,970)   *P*‐value
  --------------------------------------------------------------- --------------------- ----------------------------------- ------------------------------------- ------------------------------------------------
  Median age (years) \[interquartile range\]                      77 \[12\]             78 \[12\]                           77 \[12\]                             0.098[a](#jdi12167-note-0003){ref-type="fn"}
  Age (years)                                                                                                                                                     
  \<65                                                            567 (9.5%)            283 (9.5%)                          284 (9.6%)                            0.962
  65--74                                                          1,627 (27.4%)         809 (27.2%)                         818 (27.5%)                           
  75≦                                                             3,746 (63.1%)         1,878 (63.2%)                       1,868 (62.9)                          
  Sex                                                                                                                                                             
  Male                                                            3,137 (52.8%)         1,566 (52.7%)                       1,571 (52.9%)                         0.897
  Female                                                          2,803 (47.2)          1,404 (47.3%)                       1,399 (47.1%)                         
  Median no. months of physician visits \[interquartile range\]   7 \[9\]               11 \[2\]                            2 \[5\]                               \<0.001[a](#jdi12167-note-0003){ref-type="fn"}
                                                                                                                                                                  
  Medication for DM                                                                                                                                               
  No medication                                                   3,004 (50.6)          1,508 (50.8%)                       1,496 (50.4%)                         0.894
  OHA                                                             1,490 (25.1%)         735 (24.7%)                         755 (25.4%)                           
  Insulin                                                         803 (13.5%)           399 (13.4%)                         404 (13.6%)                           
  OHA + Insulin                                                   643 (10.8%)           328 (11.0%)                         315 (10.6%)                           
  Comorbidity                                                                                                                                                     
  AIDS/HIV                                                        0 (0.0%)              0 (0.0%)                            0 (0.0%)                              --
  Congestive heart failure                                        1,803 (30.4%)         865 (29.1%)                         938 (31.6%)                           0.039
  Chronic pulmonary disease                                       1,224 (20.6%)         646 (21.8%)                         578 (19.5%)                           0.029
  Dementia                                                        329 (5.5%)            159 (5.4%)                          170 (5.7%)                            0.533
  Hemiplegia or paraplegia                                        147 (2.5%)            66 (2.2%)                           81 (2.7%)                             0.210
  Mild liver disease                                              482 (8.1%)            259 (8.7%)                          223 (7.5%)                            0.087
  Moderate or severe liver disease                                158 (2.7%)            84 (2.8%)                           74 (2.5%)                             0.420
  Cancer                                                          1,260 (21.2%)         666 (22.4%)                         594 (20.0%)                           0.022
  Metastatic solid tumor                                          277 (4.7%)            145 (4.9%)                          132 (4.4%)                            0.424
  Peripheral vascular disease                                     218 (3.7%)            102 (3.4%)                          116 (3.9%)                            0.334
  Peptic ulcer disease                                            1,392 (23.4%)         676 (22.8%)                         716 (24.1%)                           0.220
  Rheumatological disease                                         234 (3.9%)            131 (4.4%)                          103 (3.5%)                            0.062
  Renal disease                                                   601 (10.1%)           297 (10.0%)                         304 (10.2%)                           0.763
  Charlson Comorbidity Index                                                                                                                                      
  0                                                               1,703 (28.7%)         839 (29.1%)                         864 (28.2%)                           0.705
  1--2                                                            2,505 (42.2%)         1,253 (42.2%)                       1,252 (42.2%)                         
  3≦                                                              1,732 (29.2%)         878 (28.8%)                         854 (29.6%)                           
  Other lifestyle‐related disease                                                                                                                                 
  Hypertension                                                    4,183 (70.4%)         2,088 (70.3%)                       2,095 (70.5%)                         0.842
  Hyperglycemia                                                   2,354 (39.6%)         1,175 (39.6%)                       1,179 (39.7%)                         0.915

Compared by Mann‐Whitney test. Other comparisons made using χ^2^‐test. AIDS/HIV, acquired immunodeficiency syndrome/human immunodeficiendy virus; AMI, acute myocardial infarction; IHDs, ischemic heart diseases; OHA, oral hypoglycemic agents; PAD, peripheral arterial disease.
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Multivariate Analyses {#jdi12167-sec-0012}
---------------------

Table [4](#jdi12167-tbl-0004){ref-type="table-wrap"} shows comparisons of outcomes by physician visits after propensity score matching, and AORs and 95% CIs estimated by multiple logistic regression models. The irregular visit group had a significantly higher AMI (AOR 3.52; 95% CI 1.79--6.96), other IHDs except AMI (AOR 1.25; 95% CI 1.02--1.54), all IHDs (AOR 1.37; 95% CI 1.12--1.66), all strokes (AOR 1.29; 95% CI 1.04--1.60) and risk of hospitalization for diabetic macrovascular complications (AOR 1.28; 95% CI 1.10--1.48) than did the regular visit group.

###### Comparisons of outcomes and results of multiple logistic regression analyses by physician visit after propensity score matching

                                                                 Total         Regular visit group   Irregular visit group   *P*‐value[†](#jdi12167-note-0004){ref-type="fn"}   AOR 95% CI
  -------------------------------------------------------------- ------------- --------------------- ----------------------- -------------------------------------------------- ---------------------
  Hospitalizations for AMI                                       47 (0.8%)     11 (0.4%)             36 (1.2%)               \<0.001                                            3.52 \[1.79--6.96\]
  Hospitalizations for IHDs except AMI                           424 (7.1%)    192 (6.5%)            232 (7.8%)              0.044                                              1.25 \[1.02--1.54\]
  Hospitalizations for all IHDs                                  471 (7.9%)    203 (6.8%)            268 (9.0%)              0.002                                              1.37 \[1.12--1.66\]
  Hospitalizations for ischemic stroke                           307 (5.2%)    141 (4.7%)            166 (5.6%)              0.143                                              1.17 \[0.96--1.44\]
  Hospitalizations for hemorrhagic stroke                        57 (1.0%)     21 (0.7%)             36 (1.2%)               0.046                                              1.22 \[0.97--1.54\]
  Hospitalizations for all strokes                               364 (6.1%)    162 (5.5%)            202 (6.8%)              0.030                                              1.29 \[1.04--1.60\]
  Hospitalizations for PAD                                       68 (1.1%)     40 (1.3%)             28 (0.9%)               0.143                                              0.73 \[0.45--1.19\]
  Hospitalizations for diabetic macrovascular complications      903 (15.2%)   405 (13.6%)           498 (16.8%)             0.001                                              1.28 \[1.10--1.48\]
  In‐hospital mortality[‡](#jdi12167-note-0004){ref-type="fn"}   454 (7.6%)    209 (7.0%)            245 (8.2%)              0.079                                              1.17 \[0.96--1.44\]

†Comparison made using χ^2^‐test. ‡Adjusted by sex, age, medications for diabete, hypertension, hyperglycemia and Charlson Comorbidity Index. Other models adjusted by sex, age, medications for diabetes, hypertension, hyperglycemia. Hosmer‐Lemeshow goodness for fit. *P *=* *0.940, *P *=* *0.909, *P *=* *0.706, *P *=* *0.947, *P *=* *0.684, *P *=* *0.998, *P *=* *0.129, *P *=* *0.914, *P *=* *0.070, respectively. AMI, acute myocardial infarction; AOR, adjusted odds ratio; CI, confidence interval; IHDs, ischemic heart diseases; PAD, peripheral arterial disease.
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Discussion {#jdi12167-sec-0013}
==========

We showed that there was a significant difference in the risk of hospitalization for IHD and stroke between the regular visit and irregular visit groups. The risk of hospitalization for AMI in the irregular visit group was higher than that in the regular visit group. The present study results suggest that regular visits might reduce hospitalization for diabetic macrovascular complications.

It is apparent that the regular visit group had higher adherence to treatments than did the irregular visit group. Several previous studies reported that lower adherence to medication for DM is associated with DM‐related hospitalization[23](#jdi12167-bib-0023 jdi12167-bib-0024){ref-type="ref"}. Patients who had not obtained at least 80% of their oral antihyperglycemic medication were reported to have a 2.53‐fold higher risk of subsequent hospitalization among patients with type 2 diabetes[23](#jdi12167-bib-0023){ref-type="ref"}. Similarly, patients who had a high level of adherence were found to have the lowest hospitalization rates among patients with DM, hypertension, hypercholesterolemia or congestive heart failure[24](#jdi12167-bib-0024){ref-type="ref"}.

To evaluate the risks of irregular visits more precisely, we separately estimated the rates and risks of hospitalization for stroke, IHD and PAD. We found that the risk of hospitalization for IHD was higher than that of hospitalization for stroke. A prospective cohort study in Japan reported that the incidence rate of IHD (9.68 per 1,000 person‐years) was higher than that of cerebrovascular attack (6.78 per 1,000 person‐years) among elderly type 2 DM patients[25](#jdi12167-bib-0025){ref-type="ref"}. The present results are consistent with the results of that previous study.

The present study results suggested that it would be effective for insurers to motivate beneficiaries with DM to have regular visits. Insurers, especially health insurance societies, promote lifestyle modifications aimed at enhancing health and the promotion of primary prevention[26](#jdi12167-bib-0026){ref-type="ref"}. In addition to those health activities, the Japanese government has implemented "specific health checkup and health guidance" in financial year 2008 to reduce the number of persons at high risk of lifestyle‐related diseases, including DM. Because insurers can discover the insured at high risk of lifestyle‐related diseases or those complications from specific health checkup data and incorporate that data to claims data, it is expected that insurers will develop a disease management program by using these data. To develop a disease management program, further experimental studies are necessary to evaluate the effect of interventions for making regular visits and economic effects.

There were some limitations of the present study. First, we only investigated beneficiaries of the Fukuoka National Health Insurance Organization. Second, we could not investigate clinical information, such as family history, body mass index and other laboratory values (e.g., hemoglobin A1c). However, the present study included patients who did not have outpatient visits, although most previous studies did not include these patients.

In conclusion, the present study shows that the irregular visit group had significantly higher risks of hospitalization for IHD and stroke among diabetic patients. Strategies of insurers that motivate those beneficiaries with DM to make regular visits would be effective for reducing the risk of hospitalization for IHD and stroke.
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